Alnylam Pharmaceuticals (ALNY) Change in Account Payables (2009 - 2019)

Alnylam Pharmaceuticals' Change in Account Payables history runs 11 years deep, the most recent figure standing at -$30.1 million for Q3 2019.

• Quarterly Change in Account Payables fell 431.18% year-over-year to -$30.1 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $12.4 million (up 6.22% YoY) and the FY2018 annual result came in at $15.5 million, up 413.38% from the prior year.
• Change in Account Payables was -$30.1 million for Q3 2019 at Alnylam Pharmaceuticals, down from $43.5 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $43.5 million in Q2 2019 and bottomed at -$30.1 million in Q3 2019.
• A 5-year average of $978631.6 and a median of $347000.0 in 2016 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2017 — Change in Account Payables tumbled 3289.34% — and 2019, when it surged 6377.34%.
• Alnylam Pharmaceuticals' Change in Account Payables stood at $2.6 million in 2015, then surged by 351.39% to $11.6 million in 2016, then advanced by 6.68% to $12.3 million in 2017, then surged by 30.78% to $16.1 million in 2018, then tumbled by 286.56% to -$30.1 million in 2019.
• Business Quant data shows ALNY's Change in Account Payables at -$30.1 million in Q3 2019, $43.5 million in Q2 2019, and -$17.1 million in Q1 2019.